Evidence map›Paper›PMID 33387125›Full record

ArticleDigestive diseases and sciences2021

Curcumin Chemoprevention Reduces the Incidence of Braf Mutant Colorectal Cancer in a Preclinical Study.

Alexandra M Kane, Cheng Liu, Dewan T Akhter, Diane M McKeone, Craig A Bell, Kristofer J Thurecht, Barbara A Leggett, Vicki L J Whitehall

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Alexandra M KaneQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. Alexandra.Kane@qimrberghofer.edu.au.
Cheng LiuQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Dewan T AkhterCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Bio-Nano Science and Technology, The University of Queensland, Brisbane, QLD, Australia.
Diane M McKeoneQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Craig A BellCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Bio-Nano Science and Technology, The University of Queensland, Brisbane, QLD, Australia.
Kristofer J ThurechtCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Bio-Nano Science and Technology, The University of Queensland, Brisbane, QLD, Australia.
Barbara A LeggettQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Vicki L J WhitehallQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
QIMR Berghofer Medical Research Institute · AUUniversity of Queensland · AUARC Centre of Excellence in Advanced Molecular Imaging · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer is a leading cause of cancer-related death worldwide and approximately 20% of cases can be attributed to a mutation in the BRAF oncogene. Curcumin is a promising chemopreventive agent with various anti-cancer benefits. Although curcumin has been reported to have poor bioavailability, this limitation has been overcome by the formulation of nano-carriers. In this preclinical study, we investigated the ability of an improved formulation of curcumin to reduce the incidence of Braf mutant carcinoma.

aimTo investigate curcumin as a chemopreventive for Braf mutant colorectal cancer in a preclinical study utilizing a murine model of serrated neoplasia.

methodsAn intestine-specific Braf mutant murine model (Braf

resultsAt completion of the study (14 months), it was found that curcumin did not reduce the incidence or multiplicity of murine serrated lesions but did significantly reduce the number of invasive carcinomas (RR 0.83, 95% CI 0.69-0.9985, P = 0.0360) compared to control.

conclusionsWe have performed the first long-term study assessing curcumin's effect on the development of serrated neoplasia. We found that curcumin significantly reduces the risk of developing Braf mutant colorectal cancer. Our data supports further investigation of curcumin as a chemopreventive to reduce the risk of colorectal cancer arising via the serrated pathway.

Indexed as

AnimalsAntineoplastic AgentsCarcinomaChemopreventionColorectal NeoplasmsCurcumaCurcuminDrug Screening Assays, AntitumorFemaleHumansMaleMicePhytotherapyProto-Oncogene Proteins B-rafAntineoplastic AgentsCurcuminProto-Oncogene Proteins B-rafBRAFChemopreventionColorectal cancerCurcuminPreclinicalSessile serrated lesion

Identifiers

PMID33387125
OpenAlexW3116534780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.